The FIGO staging system is the international standard for classifying cervical cancer, and its 2018 revision marked the most substantial overhaul in two decades. Under the previous 2009 framework, stage III disease was defined primarily by tumor extension to the pelvic sidewall or lower vagina and by hydronephrosis, while lymph node involvement was recorded separately and did not alter the stage. The 2018 revision changed that logic fundamentally. Any patient with proven pelvic or para-aortic lymph node metastasis, regardless of tumor dimensions, is now assigned to stage IIIC, subdivided into IIIC1 for pelvic nodes and IIIC2 for para-aortic involvement. The intention was to acknowledge the strong adverse prognostic weight of nodal disease and to bring imaging and pathology into the staging process, which previously relied on clinical examination alone.

That change, however, produced an unintended consequence that clinicians have been discussing ever since. A small tumor confined to the cervix with a single positive pelvic node and a bulky tumor invading the pelvic sidewall now share the same stage IIIC label, despite representing biologically and therapeutically distinct situations. Critics of the revision argued that the new category might obscure meaningful differences in outcome, complicating both treatment planning and the interpretation of clinical trials. The Mersin team, led by Hatice Banu Atay of the Department of Gynecologic Oncology, set out to quantify exactly how much heterogeneity the new system introduced and to test whether simple, routinely measured variables such as tumor diameter could restore prognostic clarity within the stage IIIC group.

The investigators retrospectively re-staged 212 consecutive patients with cervical cancer treated at Mersin University and affiliated hospitals between 2015 and 2025. After exclusions, 144 patients formed the final cohort, with a mean age of 54.5 years and a mean tumor diameter of 42.5 millimeters. Squamous cell carcinoma, the histologic type most closely linked to persistent human papillomavirus infection, accounted for 110 cases, or 76.4 percent of the cohort. From this group, 109 patients with early-stage disease under the older 2009 system, specifically stages IB and IIA/B, were analyzed in multivariate Cox regression models, while survival differences between the 2009 and 2018 stage III definitions were assessed with Kaplan-Meier curves and log-rank tests.

The survival contrast between the two staging eras was striking. Median survival for patients classified as stage III under FIGO 2009 was 26 months, whereas under the 2018 system the median survival for the corresponding stage III group rose to 74 months. The nearly threefold difference illustrates how the reclassification diluted the stage III category: patients with relatively favorable features, such as small primary tumors with limited nodal spread, were pulled into a stage that had previously been reserved for locally advanced disease. In other words, the same Roman numeral now describes a much more heterogeneous population, and the average outcome attached to that numeral has improved accordingly, without any change in the underlying biology or treatment.

Within the early-stage subgroup, tumor size emerged as the variable that mattered most. In the Cox regression analysis, each 1-millimeter increase in tumor diameter carried a hazard ratio of 1.064, with a 95 percent confidence interval of 1.022 to 1.108 and a p-value of 0.003, confirming an independent effect on mortality. Lymph node positivity, by contrast, was significant in univariate analysis but lost its independent prognostic value once tumor size and other factors were accounted for in multivariate models. This inversion of the expected hierarchy is notable, because nodal status was the principal rationale for creating stage IIIC in the first place. The authors caution, however, that the modest sample size limits the statistical power available to detect all but the strongest effects.

When the investigators stratified outcomes at the conventional 4-centimeter cutoff, the pattern became clearer. Patients assigned to stage IIIC under the 2018 system whose tumors measured 4 centimeters or smaller showed survival comparable to that of patients with stage I to II disease, while tumors larger than 4 centimeters predicted substantially worse outcomes. This observation supports the idea that the 4-centimeter boundary, which FIGO retained in its definitions of stage IB2, IB3 and IIA2, continues to separate two prognostically distinct populations even within the redefined stage IIIC. A small tumor with nodal involvement may behave far more like early-stage disease than like classic locally advanced cancer, a distinction with potential implications for how intensively such patients are treated and how they are counseled.

The authors are careful to frame these findings as hypothesis-generating rather than practice-changing. The stage IIIC subgroup with tumors of 4 centimeters or smaller contained only 11 patients, and no deaths were recorded in that group during follow-up, which makes any conclusion about its favorable prognosis inherently fragile. The retrospective, single-center design introduces further limitations, including the possibility of selection bias and variability in treatment protocols across the decade covered by the study. The team emphasizes that validation in larger, multicenter cohorts with standardized treatment regimens will be essential before any modification to staging or treatment algorithms could be considered on the basis of these results.

Even with those caveats, the study makes a meaningful contribution to an international conversation about how cervical cancer should be classified in the era of high-quality imaging and molecular profiling. By quantifying the survival gap between the 2009 and 2018 stage III definitions and by demonstrating the independent prognostic weight of tumor size, the Mersin data provide empirical support for proposals to subdivide stage IIIC further, perhaps incorporating tumor diameter as a formal staging parameter. The authors also note that their results feed into a national dataset and offer comparability with international standards, laying groundwork for future staging revisions and collaborative research. For clinicians managing cervical cancer today, the practical message is that the stage IIIC label should not be read in isolation: within it, a 3-centimeter tumor and a 7-centimeter tumor may represent very different diseases, and treatment intensity, trial stratification and prognostic counseling should reflect that reality. As cervical cancer remains a leading cause of cancer death among women worldwide, particularly in regions with limited screening infrastructure, refining the tools used to predict individual outcomes is not an academic exercise but a matter of clinical urgency.

Subject of Research: Prognostic heterogeneity of FIGO 2018 stage IIIC cervical cancer and the role of tumor size as an independent survival predictor

Article Title: Stage IIIC heterogeneity in FIGO 2018 cervical cancer staging: a retrospective single-center study on tumor size as an ındependent prognostic factor

Article References: Atay, H. B., Gokulu, S. G., Kıllı, M. C., Karagun, S., Gokay, D. Z., & Yıldırım, Y. (2026). Stage IIIC heterogeneity in FIGO 2018 cervical cancer staging: a retrospective single-center study on tumor size as an ındependent prognostic factor. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06602-w

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06602-w

Keywords: cervical cancer, FIGO 2018 staging, stage IIIC, tumor size, prognosis, lymph node metastasis, survival analysis, gynecologic oncology, Cox regression, cancer staging, squamous cell carcinoma, retrospective study

Cervical cancer remains a formidable challenge globally, with nodal metastasis significantly aggravating patient prognosis and complicating treatment strategies. Understanding the molecular underpinnings of this metastasis is paramount. The research team, led by Xia, M. and colleagues, delved deeply into the cellular and molecular crosstalk underlying this process, focusing on the CREB5 protein’s role in promoting lymphatic vessel formation within tumor environments.

CREB5, known as cAMP response element-binding protein 5, functions as a transcription factor regulating gene expression in various cellular contexts. Its aberrant expression and activity have been implicated in several malignancies, yet its specific contribution to cervical cancer metastasis was hitherto unclear. Employing comprehensive molecular biology techniques, the authors demonstrated that CREB5 expression correlates strongly with enhanced metastatic potential and poor clinical outcomes in cervical cancer patients.

At the heart of this metastatic cascade lies APLN, or apelin, a peptide ligand that activates the APJ receptor, participating in multiple physiological processes including angiogenesis and lymphangiogenesis. The team’s compelling data reveal that CREB5 directly upregulates APLN expression, thereby intensifying the lymphangiogenic response within tumor microenvironments. This heightened lymphangiogenesis facilitates cancer cell dissemination to regional lymph nodes, accelerating disease progression.

Subsequent functional assays affirmed that silencing CREB5 leads to a dramatic reduction in APLN levels, concomitantly diminishing lymphatic vessel formation and hindering metastatic spread in vivo. These findings underscore CREB5’s role not only as a biomarker for aggressive cervical cancer but also as an actionable molecular target whose disruption could stymie metastasis at its origin.

The researchers meticulously mapped the signaling axis connecting CREB5 to APLN-mediated pathways, uncovering a complex regulatory network that integrates environmental cues within the tumor milieu. This mechanistic insight sheds light on how cervical cancer manipulates lymphatic architecture to foster an environment conducive to tumor cell migration, fundamentally advancing our understanding of metastatic biology.

This study also highlights the interplay between tumor cells and endothelial components, illuminating how CREB5 influences lymphatic endothelial cell behavior indirectly through APLN secretion. Such paracrine signaling is instrumental in remodeling the peritumoral lymphatic system, effectively creating highways for metastatic cells to navigate.

Importantly, the elucidation of CREB5’s role offers a dual benefit: it serves as a prognostic indicator for lymph node involvement and opens up potential therapeutic modalities centered on blocking CREB5 or inhibiting the APLN-APJ signaling axis. Pharmacological blockade of this pathway might disrupt lymphangiogenesis, curtailing nodal metastases and improving survival rates.

From a clinical perspective, integrating CREB5 expression profiling into diagnostic protocols could enhance stratification of cervical cancer patients, enabling personalized treatment regimens that account for metastatic risk. Additionally, therapeutic agents targeting this pathway could be synergistically combined with existing chemoradiation therapies to overcome resistance and reduce recurrence.

Moreover, this research aligns with the broader oncological paradigm emphasizing the tumor microenvironment’s influence on cancer progression. By pinpointing lymphangiogenesis as a CRFB5-driven event, future studies may explore similar mechanisms in other malignancies where lymphatic dissemination is prevalent, potentially broadening the impact of these findings.

The versatility of CREB5 as a molecular entity also invites exploration into its upstream regulators and downstream effectors beyond APLN, delineating a more comprehensive signaling landscape that governs metastasis. Such investigations could unravel additional targets amenable to pharmaceutical intervention, further enhancing therapeutic arsenals.

Intriguingly, the fidelity of this mechanism in patient-derived samples bolsters the translational relevance of the work, suggesting that targeting the CREB5-APLN axis is not merely a theoretical exercise but a viable strategy in clinical oncology. Ongoing clinical trials may soon incorporate these molecular insights as biomarkers for patient selection or therapeutic monitoring.

This discovery also prompts a reevaluation of lymphangiogenesis inhibitors currently in development or clinical use, potentially guiding refinement toward agents that more precisely incapacitate CREB5-mediated pathways. This precision medicine approach promises to minimize off-target effects while maximizing antimetastatic efficacy.

In summary, the innovative study by Xia, M. et al. represents a milestone in cancer biology, uncovering how CREB5 reprograms cervical cancer cells to exploit lymphangiogenesis for metastatic dissemination. The implications of this work resonate strongly within the oncological community, opening new frontiers for research, diagnosis, and treatment designed to improve patient outcomes in a malignancy that continues to exact a heavy toll worldwide.

As the field advances, further corroboration of these findings and clinical translation will be critical. However, the unveiled CREB5-APLN axis firmly establishes a mechanistic foundation upon which future therapeutics and diagnostic tools can be built, signaling hope for more effective management of cervical cancer metastasis.

Subject of Research: The molecular mechanisms underlying nodal metastasis in cervical cancer, focusing on the role of CREB5 in regulating APLN-induced lymphangiogenesis.

Article Title: CREB5 promotes nodal metastasis of cervical cancer by regulation of APLN-induced lymphangiogenesis.

Article References:
Xia, M., Yuan, L., Chen, L. et al. CREB5 promotes nodal metastasis of cervical cancer by regulation of APLN-induced lymphangiogenesis. Cell Death Discov. 11, 488 (2025). https://doi.org/10.1038/s41420-025-02782-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02782-5

Radiomics, a discipline that harnesses quantitative data extracted from medical imaging, has emerged as a powerful tool in oncology. The approach allows medical professionals to visualize and quantify the intricate features of tumors that may not be discernible through traditional imaging techniques. By utilizing sophisticated algorithms, MRI radiomics generates a plethora of quantitative imaging biomarkers that can provide insights into the underlying biology of tumors. This cutting-edge application has the potential to revolutionize how oncologists interpret imaging data, moving from a purely observational practice to a more predictive and personalized approach.

In the context of cervical cancer, the microenvironment surrounding tumors plays a pivotal role in determining tumor behavior, treatment resistance, and overall prognosis. The tumor microenvironment is a complex ecosystem composed of cancer cells, immune cells, blood vessels, and extracellular matrix components that interact dynamically. These interactions can influence tumor growth and metastasis, making it imperative that researchers and clinicians alike understand these relationships to enhance treatment strategies. This study, published in the esteemed Journal of Cancer Research and Clinical Oncology, meticulously explores how MRI radiomics correlates with the characteristics of the tumor microenvironment, potentially paving the way for enhanced predictive models.

Researchers found that specific radiomic features were associated with markers of inflammation and immune response within the tumor microenvironment. These findings suggest that the information gleaned from MRI scans could provide critical context regarding the biological behavior of cervical tumors. For instance, certain radiomic patterns can indicate the presence of immunosuppressive cells or heightened inflammation, which might influence the effectiveness of immunotherapies. Knowledge of such correlations empowers oncologists to make more informed decisions about treatment options, particularly as the field shifts increasingly toward personalized medicine.

The study’s outcome is instrumental in harnessing imaging data to improve patient outcomes, particularly in a landscape where targeted therapies and immunotherapies are gaining ground. The integration of radiomics with other biomarkers could enhance the ability to stratify patients based on their risk profiles, ensuring that those most likely to benefit from aggressive treatment receive it, while others may be spared the side effects of therapies that are unlikely to succeed. The adept application of MRI radiomics thus serves not only as an imaging tool but also as a compass guiding therapeutic decisions.

However, despite the promise of MRI radiomics, significant challenges remain in the field. The reliance on high-quality imaging, variations in interpretation across different institutions, and the need for large validation studies are crucial obstacles that researchers must overcome. Standardization of imaging protocols and radiomic extraction methodologies will be vital to Ubiquitously implementing this innovative approach in clinical practice. Multi-center collaborations and large-scale cohort studies may help bridge these gaps, ensuring that the findings can be generalized across diverse populations and healthcare settings.

The implications of such research extend beyond cervical cancer alone. The fundamental principles of integrating MRI radiomics with tumor microenvironment assessments could be extrapolated to other malignancies, advancing the understanding of tumor biology across cancers. As such, ongoing investigations that seek to confirm and expand these findings will be critical in establishing MRI radiomics as a cornerstone in contemporary oncology.

The research methodology employed in this study illustrates the rigor necessary to validate the relationship between MRI radiomics and cancer pathology. The use of advanced imaging algorithms and machine learning techniques provides a robust framework for uncovering associations that may be missed through conventional analysis. By employing multifaceted statistical approaches, the authors were able to delineate connections between specific MRI characteristics and various components of the tumor microenvironment, leading to an enriched understanding of tumor behavior.

Moreover, the synergy between imaging, pathology, and clinical variables cannot be overlooked. The findings advocate for an interdisciplinary approach whereby radiologists, pathologists, and oncologists collaborate in interpreting data derived from MRI radiomics. Such collaboration will facilitate a holistic understanding of cancer evolution and inter-tumoral heterogeneity, ultimately improving patient care pathways.

As the landscape of cancer research evolves, the integration of artificial intelligence and machine learning into radiomics will further enhance the predictive capacity of imaging analysis. Technological advancements will likely lead to the development of even more sophisticated algorithms that can process imaging data at unprecedented speeds and accuracies. This trajectory indicates a future where decision-making in oncology is not only faster but also more evidence-based and tailor-made to the individual patient’s needs.

Looking ahead, it will be crucial to disseminate these findings beyond academic circles. Engaging healthcare practitioners, policymakers, and funding bodies in discussions about the potency of MRI radiomics in personalized medicine is necessary to propel this field forward. By fostering awareness and understanding among stakeholders, the research community can amplify the translation of these findings into clinical practice, enhancing the potential for improved patient outcomes.

In summary, the groundbreaking research conducted by Meyer and colleagues offers promising insights into the intersection of MRI radiomics and the tumor microenvironment in uterine cervical cancer. It paves the way for a future where precise imaging methods can inform more personalized treatment regimens, which could dramatically change the standard of care for patients battling this challenging disease. As the research community continues to unravel the complexities of cancer biology, the marriage of imaging technology with tumor pathology represents a significant leap toward more effective and individualized cancer therapies.

Through their bold exploration of these interconnections, the authors highlight the vital role that advanced imaging technologies can play in reshaping oncology. As we stand on the brink of a new era in cancer treatment and diagnosis, the promise of MRI radiomics will undoubtedly drive innovations that will better combat one of society’s most formidable health challenges.

Subject of Research: MRI radiomics analysis and tumor micro milieu in uterine cervical cancer.

Article Title: Associations between MRI radiomics analysis and tumor-micro milieu in uterine cervical cancer.

Article References:

Meyer, HJ., Leonhardi, J., Höhn, AK. et al. Associations between MRI radiomics analysis and tumor-micro milieu in uterine cervical cancer. J Cancer Res Clin Oncol 151, 219 (2025). https://doi.org/10.1007/s00432-025-06253-3

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06253-3

Keywords: MRI radiomics, cervical cancer, tumor microenvironment, personalized medicine, imaging biomarkers.